Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.

Britain's Terry Smith made public for the first time why Fundsmith Equity Fund dumped its Diageo stake last year.

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Stada has lined up a new independent chairman and board of directors in a key step for the private equity-backed German drug ...